Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 6/20 | 1.00 |
| ▸ | HPGDS | O60760 | 7/20 | 0.57 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.55 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | NQO2 | P16083 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.45 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.45 |
| ▸ | CASP3 | P42574 | 1/20 | 0.45 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30241125 | 1.00 | EGFR (1.00) | EGFRHPGDSPDGFRBPDGFRANPC1 | |
| SCHEMBL29517021 | 1.00 | EGFR (1.00) | EGFRHPGDSPDGFRBPDGFRANPC1 | |
| Hydrochloric Acid SCHEMBL28023744 | 0.98 | EGFR (0.96) | EGFRHPGDSPDGFRBPDGFRANPC1 | |
| SCHEMBL31728944 | 0.88 | EGFR (0.78) | EGFRHPGDSPDGFRBPDGFRAPDE10A | |
| SCHEMBL27976752 | 0.86 | EGFR (0.76) | EGFRPDGFRBPDGFRANPC1RAB9A | |
| SCHEMBL3372138 | 0.85 | EGFR (1.00) | EGFRHPGDSPDGFRBPDGFRANPC1 | |
| SCHEMBL13837704 | 0.85 | EGFR (0.73) | EGFRHPGDSPDGFRBPDGFRA | |
| SCHEMBL30979881 | 0.84 | EGFR (0.73) | EGFRHPGDSPDGFRBPDGFRANPC1 | |
| Hydrochloric Acid SCHEMBL28032872 | 0.84 | EGFR (0.96) | EGFRHPGDSPDGFRBPDGFRANPC1 | |
| SCHEMBL4649110 | 0.82 | EGFR (0.70) | EGFRPDGFRBPDGFRAALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118852129-A | Preparation method and application of triazole feed additive with anti-inflammatory activity designed based on deep learning technology | 河南湾流生物科技有限公司 | 2024-10-29 | — | — | CN | claimed |
| US-20230321049-A1 | COMPOSITIONS OF ENPP1 INHIBITORS AND USES THEREOF | Petragen, Inc. | 2023-10-12 | — | — | US | claimed |
| WO-2013050527-A1 | QUINAZOLINE DERIVATIVES AS PDE10A ENZYME INHIBITORS | H. LUNDBECK A/S (DK) | 2013-04-11 | — | — | WO | claimed |
| US-20110201628-A1 | HETEROCYCLIC JAK KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2011-08-18 | — | — | US | claimed |
| EP-2346507-A1 | USE OF QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF VIRAL DISEASES | Boehringer Ingelheim International GmbH (DE) | 2011-07-27 | — | — | EP | claimed |
| EP-2346859-A1 | HETEROCYCLIC JAK KINASE INHIBITORS | AstraZeneca AB (SE) | 2011-07-27 | — | — | EP | claimed |
| WO-2010038060-A1 | HETEROCYCLIC JAK KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2010-04-08 | — | — | WO | claimed |
| WO-2010026029-A1 | USE OF QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF VIRAL DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-03-11 | — | — | WO | claimed |
| EP-2086641-A2 | EGFR KINASE INHIBITOR COMBINATIONS FOR THE TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISORDERS | Boehringer Ingelheim International GmbH (DE) | 2009-08-12 | — | — | EP | claimed |
| WO-2008049842-A2 | EGFR KINASE INHIBITOR COMBINATIONS FOR THE TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-05-02 | — | — | WO | claimed |
| EP-1784224-A2 | EGFR KINASE INHIBITOR COMBINATIONS FOR TREATING RESPIRATORY AND GASTROINTESTINAL DISORDERS | Boehringer Ingelheim International GmbH (DE) | 2007-05-16 | — | — | EP | claimed |
| JP-2007505878-A | — | — | 2007-03-15 | — | — | JP | claimed |
| EP-1706119-A1 | NOVEL PHARMACEUTICAL COMBINATIONS CONTAINING SCOPINE OR TROPIC ACID ESTERS AND EGFR-KINASE INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2006-10-04 | — | — | EP | claimed |
| WO-2006082129-A1 | USE OF TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CHRONIC RHINOSINUSITIS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-08-10 | — | — | WO | claimed |
| EP-1670782-A1 | QUINAZOLINE DERIVATIVES | AstraZeneca AB (SE) | 2006-06-21 | — | — | EP | claimed |
| WO-2006015775-A2 | EGFR KINASE INHIBITOR COMBINATIONS FOR TREATING RESPIRATORY AND GASTROINTESTINAL DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-02-16 | — | — | WO | claimed |
| WO-2005065687-A1 | NOVEL PHARMACEUTICAL COMBINATIONS CONTAINING SCOPINE OR TROPIC ACID ESTERS AND EGFR-KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-07-21 | — | — | WO | claimed |
| WO-2005028470-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2005-03-31 | — | — | WO | claimed |
| CN-1178938-C | 1,2-annelated quinoline derivatives | ղɭҩҵ����˾ | 2004-12-08 | — | — | CN | claimed |
| CN-1331693-A | 1,2-annelated quinoline derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2002-01-16 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201628-A1 | HETEROCYCLIC JAK KINASE INHIBITORS | JAK2, JAK1, JAK3 | EGFR 469/4885HPGDS 179/4885PDGFRB 260/4885 |
| US-20230321049-A1 | COMPOSITIONS OF ENPP1 INHIBITORS AND USES THEREOF | ENPP1, ENPP2, ENPP3 | EGFR 3329/4885HPGDS 775/4885PDGFRB 1156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.